CD8A and neoplasm: Furthermore, when we compared the preclinical performance of the [89Zr]Zr-hCD103.Fab01A tracer with that of the [89Zr]Zr-DFO-CD8a F(ab)'2 tracer[29] in syngeneic mice, both tracers showed a comparable uptake in the xenografts at the selected scan time point ([89Zr]Zr-hCD103.Fab01A vs [89Zr]Zr-DFO-CD8a F(ab)’2, mean %ID/g: 2.28 vs 2.44, mean xenograft/tumor-to-blood ratio 13.33 vs 14.69).